Insider Cluster (3 insiders) ·Filed Jul 2, 2026

CTNM

Contineum Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago
Insider cluster: 3 insiders, $0.8M total
Actionable Insight • Neutral

This cluster is a vesting-driven sell pattern, not a material bearish signal. Monitor for any follow-on open-market sales by these insiders over the next 30 days; if additional sales occur without prior derivative exercises, the signal would strengthen. The company has no cross-filing context suggesting distress (no NT, no offering, no restatement), so this cluster alone does not warrant a bearish read.

DirectionNeutral
Confidencehigh
Horizondays
Latest settled — T+60d ⚠ clustered
CTNM ▼ -17.28% at T+60d
NEUTRAL call ✗ call lost -17.28% · α vs SPY -20.29% · entry $15.10 → $12.49
Next anchor: T+1d due 3mo ago
Entry anchored
Jul 1, 03:59 PM ET
via exchange tick
T+1d
—
call — · α —
—
due 3mo ago
T+5d
+2.32%
call +2.32% · α +1.39%
$15.45
settled 3mo ago
T+20d
+4.30%
call +4.30% · α +4.72%
$15.75
settled 2mo ago
T+60d
-17.28%
call -17.28% · α -20.29%
$12.49
settled 7d ago

Price Chart

Loading chart...

Executive Summary

Three top insiders (CEO, CSO, and CMO) at Contineum Therapeutics exercised and sold shares in a coordinated cluster totaling ~$796K in open-market sales on June 30, 2026. The cluster is entirely sell-side with a clear pattern of derivative exercises paired with immediate share sales, indicating a liquidity/vesting-driven event rather than a uniform bearish conviction call. At ~0.14% of the $570M market cap, the total is modest and within routine proportionality, despite the C-suite breadth.

Key Financial Metrics

Direction
selling
Total Value
$796.0K
Insiders
3

Key Facts

  • Three insiders sold 37,186 shares in open-market sales on June 30- July 1, 2026, totaling ~$796K.
  • CEO Carmine Stengone sold 10,000 shares ($160K); CSO Daniel Lorrain sold 28,826 shares ($462K); CMO Tim Watkins sold 10,833 shares ($174K).
  • Each insider exercised stock options (prices $0-$4.50) immediately prior to or concurrent with the sales — a typical vesting-and-sell pattern.
  • Total open-market sales represent ~0.14% of the company's $570M market cap — below the 0.5% threshold for a notable cluster.

Financial Impact

Total insider sales of $796K, representing 0.14% of market cap; non-cash derivative exercises had no market impact.

dilutioninsider ownership

Risk Factors

  • Insider selling tends to be a weak forward indicator for a single cluster; cluster sells are less informative than cluster buys per the literature.
  • The historical T+20 performance on prior CTNM reports has been negative, but those were neutral on different content — not directly applicable here.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CTNM-1783063046737
4 reports for CTNM
Performance horizon
Filters
Rows
Reports for CTNM — sortable, filterable
TypeNow
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$15.45 $13.12▼ −15.08%▼ −16.71%$13.12 (−15.08%)
Jul 2, 2026
13w ago
Insider Cluster
NEUTRAL ★ 3/10
$15.10 $12.49▼ −17.28%▼ −20.29%$13.12 (−13.11%)
Jul 1, 2026
13w ago
Insider Cluster
NEUTRAL ★ 2/10
$15.10 $12.49▼ −17.28%▼ −20.29%$13.12 (−13.11%)
Mar 5, 2026
30w ago
8-K
NEUTRAL ★ 5/10
$13.88 $13.09▼ −5.69%▼ −18.47%$13.12 (−5.48%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (37h 50m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 3, 2026